|Day Low/High||27.01 / 28.06|
|52 Wk Low/High||36.49 / 83.69|
The market isn't buying that Trump is bad for business
Such unwarranted fears have depressed the sector, which could bounce back after Nov. 8.
'If there are worries about the market topping out it isn't evident in [today's] price action.'
Biotechnology stocks can be risky but it's helpful to track them over time.
Shares of Global Blood Therapeutics currently are in the bargain bin.
We are seeing lower lows in the indices as I write.
It's challenging to put cash to work but I'll keep digging.
Meanwhile, I continue to hold long-term favorites like Energy Recovery, TPI Composites and Aratana.
Buyers expect a dovish Fed and are still trying to put money to work.
Despite the unsettled market, there are still some interesting picks out there.
The overall technical condition of the indices remains negative.
If the market closes weak today, it will be marked with an exclamation point.
Upside momentum is limited, but we still aren't seeing any major technical breakdowns.
Until there is a change in the character of this action, it pays to be bullish.
Ideally I'd like to buy a negative response to Janet Yellen tomorrow.
The sudden dearth of momentum will give us some good opportunities, but watch accounts closely.
Make sure you protect those outsized gains; this is a great market for stock picking.
Global Blood Therapeutics is a good example of how tracking a chart and waiting for a setup can work well.
If you follow the adage about cutting losses quickly and letting winners run, it is possible to generate some very attractive returns.
Microsoft is doing the deal partly because it can fund it so easily.
I can't recall every hearing so many negative predictions from big-picture bears.